Why Merck (MRK) is a Top Momentum Stock for the Long-Term
https://www.zacks.com/stock/news/2277274/why-merck-mrk-is-a-top-momentum-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2277274
May 22, 2024 - The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
0
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
https://www.zacks.com/stock/news/2275940/here-s-why-merck-mrk-stock-has-outperformed-industry-ytd?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2275940
May 20, 2024 - Merck (MRK) stock is being driven by the strong sales of key products like Keytruda and Gardasil and positive pipeline and regulatory developments.
0
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
https://www.zacks.com/stock/news/2275562/pharma-stock-roundup-bayry-s-q1-earnings-jnj-s-new-buyout-pipeline-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2275562
May 17, 2024 - Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
0
Merck (MRK) Crossed Above the 20-Day Moving Average: What That Means for Investors
https://www.zacks.com/stock/news/2274678/merck-mrk-crossed-above-the-20-day-moving-average-what-that-means-for-investors?cid=CS-ZC-FT-tale_of_the_tape|20_day_moving_average_(yseop)-2274678
May 16, 2024 - When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
0
Top Stock Reports for Broadcom, Merck & Airbnb
https://www.zacks.com/commentary/2274193/top-stock-reports-for-broadcom-merck-airbnb?cid=CS-ZC-FT-research_daily-2274193
May 15, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Merck & Co., Inc. (MRK) and Airbnb, Inc. (ABNB).
0
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
https://www.zacks.com/stock/news/2272954/bristol-myers-bmy-fails-to-meet-goal-in-opdivo-nsclc-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2272954
May 13, 2024 - Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
0
Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
https://www.zacks.com/stock/news/2272311/pharma-stock-roundup-pfe-dmd-study-patient-death-fda-panel-meet-for-lly-s-donanemab?cid=CS-ZC-FT-analyst_blog|stock_roundup-2272311
May 10, 2024 - Pfizer (PFE) reports the death of a participant in a mid-stage study of its Duchenne drug. An FDA panel meeting to discuss Eli Lilly's (LLY) donanemab is set to take place on Jun 10.
0
A Look at Pharma ETFs Post Q1 Earnings
https://www.zacks.com/stock/news/2269782/a-look-at-pharma-etfs-post-q1-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2269782
May 07, 2024 - Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
0
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
https://www.zacks.com/stock/news/2267310/moderna-mrna-q1-earnings-beat-estimates-revenues-down-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2267310
May 02, 2024 - Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
0
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
https://www.zacks.com/stock/news/2264391/moderna-mrna-gears-up-for-q1-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_article-2264391
Apr 29, 2024 - Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
0